Sector News

PhRMA throws controversy-ridden Valeant under the bus

October 23, 2015
Life sciences

Pharma industry trade group PhRMA generally protects its own amid controversy. But now, it’s put up a statement on its website criticizing a drugmaker that’s surrounded by plenty.

Thursday, the group likened the Canadian drugmaker Valeant Pharmaceuticals to much-maligned Turing Pharmaceuticals, noting that its strategy is “more reflective of a hedge fund than an innovative biopharmaceutical company.”

Unlike Valeant, the innovators “have R&D at the core–and the numbers to prove it,” the post says. The Quebec-based pharma, on the other hand, has made its way by serially acquiring companies and squeezing out costs, investing on average less than 3% of its total revenue on R&D.

It’s the latest effort by the group to distance itself from the drug price uproar coming from lawmakers, presidential candidates and–in the case of Valeant–federal prosecutors. Earlier this week, short seller Citron Research likened Valeant to Enron and claimed it used its relationship with specialty pharmacies to inflate its top line; that relationship was one of the subjects of a pair of federal subpoenas the company last week announced it had received.

Turing, which drew ire when it last month hiked the price of Daraprim by more than 5000%, felt a similar burn from the trade organization when PhRMA put out a tweet stating that the company didn’t represent the values of its member companies.

Meanwhile, Valeant said Monday that it’s looking to sock more money into R&D. It’ll also look to hive off its neurology and “other drugs” unit, which has been subject to some of its biggest price hikes, and it’ll pursue fewer–if any–transactions “focused on mispriced products,” CEO J. Michael Pearson said on a conference call.

But those assurances didn’t do much to sooth investors’ worries when Citron’s “phantom sales” allegations hit. After plunging 19% Wednesday, Valeant’s share price dropped another 7.4%, Bloomberg points out, with one BMO Capital Markets analyst downgrading the stock.

By Carly Helfand

Source: Fierce Pharma

Related News

April 17, 2021

Thermo Fisher to buy research contractor PPD in $17B deal

Life sciences

Thermo Fisher Scientific plans to buy PPD for $17.4 billion to bolster its clinical research service offerings to pharmaceutical and biotech companies.

April 17, 2021

Nestlé finds supplement cocktail slashes preterm birth in major preconception study

Life sciences

Nestlé Research has linked a specific blend of myo-inositol (a type of sugar), probiotics, riboflavin, zinc and vitamins D, B6 and B12 to the decreased incidence of preterm birth when consumed before and during pregnancy.

April 17, 2021

Eli Lilly, riding pharma’s rising digital wave, drafts Apple exec to replace Shah as CDO

Life sciences

Eli Lilly hired a new digital chief from Apple in another consumer switch for pharma and as the industry speeds up its shift to online strategies.

Send this to a friend